Yisheng’s biological product for pancreatic cancer gets Orphan Drug Designation

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Yisheng Biopharma Co., Ltd., said the FDA has granted orphan drug designation for its lead immuno-oncology candidate, YS-ON-001, for pancreatic cancer.

To date, FDA has granted YS-ON-001 two ODDs for the treatment of pancreatic cancer and hepatocellular carcinoma. YS-ON-001 is a clinical-stage immuno-oncology biologic product with unique immunomodulating mechanism and broad spectrum of anti-tumor activity.

YS-ON-001 is a clinical stage biological product based on our proprietary immunomodulating cell technology developed in-house at Yisheng Biopharma. It is a multi-component complex with broad immunomodulating properties, such as promoting Th1-biased immunity, inducing the activation and proliferation of dendritic cell, B and natural killer cells, promoting macrophage M1 polarization and downregulating regulatory T cells.

YOU MAY BE INTERESTED IN

The day before health economist Jay Bhattacharya stepped into his new role as NIH director, he sent a document to his employees outlining his top five priorities for the department, which included “reproducibility” and “transparency,” two themes he discussed at his confirmation hearings (The Cancer Letter, March 7, 2025).

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login